Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ACACB | O00763 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | LCAT | P04180 | 1/20 | 0.37 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14966335 | 0.90 | MAPT (0.48) | CYP2C9CYP2C19MAPTSMN1; SMN2KDM4E | |
| SCHEMBL14966413 | 0.90 | CHRM4 (0.44) | CYP2C9CYP2C19MAPTSMN1; SMN2KDM4E | |
| SCHEMBL14965924 | 0.85 | POLB (0.47) | CYP2C9CYP2C19MAPTSMN1; SMN2KDM4E | |
| SCHEMBL14966416 | 0.83 | KCNH2 (0.45) | CHRM1CHRM3CHRM2CHRM5CHRM4 | |
| SCHEMBL14966355 | 0.82 | CXCR3 (0.47) | CYP2C9CYP2C19MAPTSMN1; SMN2KDM4E | |
| SCHEMBL14966405 | 0.82 | TP53 (0.46) | CYP2C9CYP2C19MAPTSMN1; SMN2KDM4E | |
| SCHEMBL14966608 | 0.81 | CHRM4 (0.47) | CYP2C9CYP2C19MAPTSMN1; SMN2KDM4E | |
| SCHEMBL14969317 | 0.79 | KCNH2 (0.43) | CHRM1CHRM3CHRM2CHRM5CHRM4 | |
| SCHEMBL14978692 | 0.79 | BTK (0.42) | CYP2C9CYP2C19SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL14966344 | 0.79 | CHRM4 (0.44) | CYP2C9CYP2C19MAPTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309226-A1 | PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2014-10-16 | — | — | US | disclosed |
| WO-2013074641-A1 | PIPERIDINYL- SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | ARRAY BIOPHARMA INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309226-A1 | PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | GPR119, UTS2R, GPR139 | CYP2C9 1002/4885CYP2C19 879/4885MAPT 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.